TY - JOUR
T1 - Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas
AU - Martucci, Victoria L.
AU - Emaminia, Abbas
AU - Del Rivero, Jaydira
AU - Lechan, Ronald M.
AU - Magoon, Bindiya T.
AU - Galia, Analyza
AU - Fojo, Tito
AU - Leung, Steve
AU - Lorusso, Roberto
AU - Jimenez, Camilo
AU - Shulkin, Barry L.
AU - Audibert, Jennifer L.
AU - Adams, Karen T.
AU - Rosing, Douglas R.
AU - Vaidya, Anand
AU - Dluhy, Robert G.
AU - Horvath, Keith A.
AU - Pacak, Karel
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/6/15
Y1 - 2015/6/15
N2 - Pheochromocytomas and paragangliomas are chromaffin cell tumors arising from neuroendocrine cells. At least 1/3 of paragangliomas are related to germline mutations in 1 of 17 genes. Although these tumors can occur throughout the body, cardiac paragangliomas are very rare, accounting for <0.3% of mediastinal tumors. The purpose of this study was to determine the clinical characteristics of patients with cardiac paragangliomas, particularly focusing on their genetic backgrounds. A retrospective chart analysis of 15 patients with cardiac paragangliomas was performed to determine clinical presentation, genetic background, diagnostic workup, and outcomes. The average age at diagnosis was 41.9 years. Typical symptoms of paraganglioma (e.g., hypertension, sweating, palpitations, headache) were reported at initial presentation in 13 patients (86.7%); the remaining 2, as well as 4 symptomatic patients, initially presented with cardiac-specific symptoms (e.g., chest pain, dyspnea). Genetic testing was done in 13 patients (86.7%); 10 (76.9%) were positive for mutations in succinate dehydrogenase (SDHx) subunits B, C, or D. Thirteen patients (86.7%) underwent surgery to remove the paraganglioma with no intraoperative morbidity or mortality; 1 additional patient underwent surgical resection but experienced intraoperative complications after removal of the tumor due to co-morbidities and did not survive. SDHx mutations are known to be associated with mediastinal locations and malignant behavior of paragangliomas. In this report, the investigators extend the locations of predominantly SDHx-related paragangliomas to cardiac tumors. In conclusion, cardiac paragangliomas are frequently associated with underlying SDHx germline mutations, suggesting a need for genetic testing of all patients with this rare tumor.
AB - Pheochromocytomas and paragangliomas are chromaffin cell tumors arising from neuroendocrine cells. At least 1/3 of paragangliomas are related to germline mutations in 1 of 17 genes. Although these tumors can occur throughout the body, cardiac paragangliomas are very rare, accounting for <0.3% of mediastinal tumors. The purpose of this study was to determine the clinical characteristics of patients with cardiac paragangliomas, particularly focusing on their genetic backgrounds. A retrospective chart analysis of 15 patients with cardiac paragangliomas was performed to determine clinical presentation, genetic background, diagnostic workup, and outcomes. The average age at diagnosis was 41.9 years. Typical symptoms of paraganglioma (e.g., hypertension, sweating, palpitations, headache) were reported at initial presentation in 13 patients (86.7%); the remaining 2, as well as 4 symptomatic patients, initially presented with cardiac-specific symptoms (e.g., chest pain, dyspnea). Genetic testing was done in 13 patients (86.7%); 10 (76.9%) were positive for mutations in succinate dehydrogenase (SDHx) subunits B, C, or D. Thirteen patients (86.7%) underwent surgery to remove the paraganglioma with no intraoperative morbidity or mortality; 1 additional patient underwent surgical resection but experienced intraoperative complications after removal of the tumor due to co-morbidities and did not survive. SDHx mutations are known to be associated with mediastinal locations and malignant behavior of paragangliomas. In this report, the investigators extend the locations of predominantly SDHx-related paragangliomas to cardiac tumors. In conclusion, cardiac paragangliomas are frequently associated with underlying SDHx germline mutations, suggesting a need for genetic testing of all patients with this rare tumor.
UR - http://www.scopus.com/inward/record.url?scp=84930181989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930181989&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.03.020
DO - 10.1016/j.amjcard.2015.03.020
M3 - Article
C2 - 25896150
AN - SCOPUS:84930181989
SN - 0002-9149
VL - 115
SP - 1753
EP - 1759
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 12
M1 - 21058
ER -